Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinson’s disease

Santaella, Anna; Kuiperij, H. Bea; Rumund, Anouke van; Esselink, Rianne A.J.; Gool, Alain J. van; Bloem, Bastiaan R.; Verbeek, Marcel M.

doi:10.1038/s41531-020-00124-z

Cited by 21 publications

(18 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MCP-1 is a chemokine that is expressed by glial cells and neurons. Higher plasma MCP-1 levels are associated with more rapid and severe cognitive decline secondary to neuronal loss whereas lower levels are neuroprotective [35,36]. There is emerging data showing that MCP-1 acts as a potent chemotactic factor regulating stromalepithelial cell in prostate cancer.…”

Section: Discussionmentioning

confidence: 99%

Effects of yoga in men with prostate cancer on quality of life and immune response: a pilot randomized controlled trial

Kaushik

Shah²,

Mukherjee³

et al. 2021

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Background Diagnosis and treatment of prostate cancer is associated with anxiety, fear, and depression in up to one-third of men. Yoga improves health-related quality of life (QoL) in patients with several types of cancer, but evidence of its efficacy in enhancing QoL is lacking in prostate cancer. Methods In this randomized controlled study, 29 men newly diagnosed with localized prostate cancer were randomized to yoga for 6 weeks (n = 14) or standard-of-care (n = 15) before radical prostatectomy. The primary outcome was self-reported QoL, assessed by the Expanded Prostate Index Composite (EPIC), Functional Assessment of Cancer Therapy-Prostate (FACT-P), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT–F), Functional Assessment of Cancer Therapy-General (FACT-G) at baseline, preoperatively, and 6 weeks postoperatively. Secondary outcomes were changes in immune cell status and cytokine levels with yoga. Results The greatest benefit of yoga on QoL was seen in EPIC-sexual (mean difference, 8.5 points), FACIT-F (6.3 points), FACT-Functional wellbeing (8.6 points), FACT-physical wellbeing (5.5 points), and FACT-Social wellbeing (14.6 points). The yoga group showed increased numbers of circulating CD4+ and CD8+ T-cells, more production of interferon-gamma by natural killer cells, and increased Fc receptor III expression in natural killer cells. The yoga group also showed decreased numbers of regulatory T-cells, myeloid-derived suppressor cells, indicating antitumor activity, and reduction in inflammatory cytokine levels (granulocyte colony-stimulating factor [0.55 (0.05–1.05), p = 0.03], monocyte chemoattractant protein [0.22 (0.01–0.43), p = 0.04], and FMS-like tyrosine kinase-3 ligand [0.91 (−0.01, 1.82), p = 0.053]. Conclusions Perioperative yoga exercise improved QoL, promoted an immune response, and attenuated inflammation in men with prostate cancer. Yoga is feasible in this setting and has benefits that require further investigation. Trial registration clinicaltrials.org (NCT02620033).

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of yoga in men with prostate cancer on quality of life and immune response: a pilot randomized controlled trial

Kaushik

Shah²,

Mukherjee³

et al. 2021

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…NLK has also been investigated in the context of other neurodegenerative diseases: in a transgenic mouse model of Huntington’s disease, the NLK gene was upregulated [ 34 ]. Furthermore, in patients with Parkinson’s disease and multiple system atrophy, CSF NLK levels were normal [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

“…NLK was quantified in CSF using the human glucose-6-phosphate isomerase ELISA kit (cat no. Ab171575; Abcam, Cambridge, UK) according to the manufacturers’ instructions [ 25 ]. A standard curve ranging from 156 to 10,000 pg/ml was constructed using serial two-fold dilutions.…”

Section: Methodsmentioning

confidence: 99%

Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Neuroleukin (NLK) is a protein with neurotrophic properties and is present in a proportion of senile plaques and amyloid laden vessels. It has been suggested that NLK is part of a neuroprotective response to amyloid β-induced cell death. The aim of our study was to investigate the value of cerebrospinal fluid (CSF) NLK levels as a biomarker of vascular amyloid deposition in patients with cerebral amyloid angiopathy (CAA) and in patients with amnestic mild cognitive impairment (aMCI) and Alzheimer’s disease (AD). Methods CSF NLK levels were quantified by ELISA in CAA patients (n = 25) and controls (n = 27) and in two independent samples of aMCI patients, AD patients, and controls: (1) From the Radboud University Medical Center (Nijmegen), we included n = 19 aMCI patients, n = 40 AD patients, and n = 32 controls. (2) From the Hospital of Sant Pau (Barcelona), we included n = 33 aMCI patients, n = 17 AD patients, and n = 50 controls. Results CSF NLK levels were similar in CAA patients and controls (p = 0.95). However, we found an elevated CSF concentration of NLK in aMCI (p < 0.0001) and AD patients (p < 0.0001) compared to controls in both samples sets. In addition, we found a correlation of CSF NLK with CSF YKL-40 (age-adjusted-spearman-rank-coefficient = 0.82, p < 0.0001) in aMCI/AD patients, a well-known glial marker of neuro-inflammation. Conclusions We found that CSF NLK levels are elevated in aMCI and AD patients compared to controls, but are not increased in CAA patients. CSF NLK levels may be related to an increased neuroinflammatory state in early stages of AD, given its association with YKL-40.

show abstract

“…Elevated MCP-1 levels were detected in the CSF of PD [ 75 ] as well as MSA patients in comparison to controls [ 76 ]. On the contrary, other studies reported comparable MCP-1 levels in the CSF among PD, MSA and controls [ 77 , 78 , 79 , 80 , 81 , 82 ]. These discrepancies might be explained by clinical heterogeneity, diagnostic uncertainties and different assays used.…”

Section: Inflammatory Biomarkersmentioning

confidence: 75%

Update on CSF Biomarkers in Parkinson’s Disease

et al. 2022

View full text Add to dashboard Cite

Progress in developing disease-modifying therapies in Parkinson’s disease (PD) can only be achieved through reliable objective markers that help to identify subjects at risk. This includes an early and accurate diagnosis as well as continuous monitoring of disease progression and therapy response. Although PD diagnosis still relies mainly on clinical features, encouragingly, advances in biomarker discovery have been made. The cerebrospinal fluid (CSF) is a biofluid of particular interest to study biomarkers since it is closest to the brain structures and therefore could serve as an ideal source to reflect ongoing pathologic processes. According to the key pathophysiological mechanisms, the CSF status of α-synuclein species, markers of amyloid and tau pathology, neurofilament light chain, lysosomal enzymes and markers of neuroinflammation provide promising preliminary results as candidate biomarkers. Untargeted approaches in the field of metabolomics provide insights into novel and interconnected biological pathways. Markers based on genetic forms of PD can contribute to identifying subgroups suitable for gene-targeted treatment strategies that might also be transferable to sporadic PD. Further validation analyses in large PD cohort studies will identify the CSF biomarker or biomarker combinations with the best value for clinical and research purposes.

show abstract

Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinson’s disease

Cited by 21 publications

References 46 publications

Effects of yoga in men with prostate cancer on quality of life and immune response: a pilot randomized controlled trial

Effects of yoga in men with prostate cancer on quality of life and immune response: a pilot randomized controlled trial

Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy

Update on CSF Biomarkers in Parkinson’s Disease

Contact Info

Product

Resources

About